1. Home
  2. BNCWW vs SCLXW Comparison

BNCWW vs SCLXW Comparison

Compare BNCWW & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CEA Industries Inc. Warrant

BNCWW

CEA Industries Inc. Warrant

N/A

Current Price

$0.03

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

N/A

Current Price

$0.12

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BNCWW
SCLXW
Founded
N/A
N/A
Country
United States
United States
Employees
164
30
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BNCWW
SCLXW
Price
$0.03
$0.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
9.9K
2.4K
Earning Date
N/A
03-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$55,152,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.02
52 Week Low
$0.02
$0.04
52 Week High
$0.31
$0.64

Technical Indicators

Market Signals
Indicator
BNCWW
SCLXW
Relative Strength Index (RSI) 40.78 44.87
Support Level $0.02 $0.10
Resistance Level $0.05 $0.18
Average True Range (ATR) 0.01 0.02
MACD -0.00 -0.00
Stochastic Oscillator 14.39 39.40

Price Performance

Historical Comparison
BNCWW
SCLXW

About BNCWW CEA Industries Inc. Warrant

CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: